Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Saved in:
| Title: | Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer. |
|---|---|
| Authors: | Dadi N; Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, U.S.A., Stanley M; Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, U.S.A., Shahda S; Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, U.S.A., O'Neil BH; Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, U.S.A., Sehdev A; Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, U.S.A. asehdev@iupui.edu.; Center for Health Services Research, Regenstrief Institute, Indianapolis, IN, U.S.A.; Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, IN, U.S.A. |
| Source: | Anticancer research [Anticancer Res] 2017 Oct; Vol. 37 (10), pp. 5533-5539. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model: Print Cited Medium: Internet ISSN: 1791-7530 (Electronic) Linking ISSN: 02507005 NLM ISO Abbreviation: Anticancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
